This is an open-labelled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of the single-dose primary immunization of live attenuated varicella vaccine on different time points ,and the safety and immunogenicity after the booster immunization
This study is an open-labelled phase Ⅲ clinical trial.The experimental vaccine manufactured by Sinovac(Dalian) Vaccine Technology Co., Ltd.A total of 1195 subjects who received vaccine in the phase Ⅲ lot-consistency clinical trial were be enrolled .All subjects except C0243 and C0556 were divided into 3 groups according to the order of study number.Subjects in 3 groups received a booster immunization of live attenuated varicella vaccines 1 year,2 years and 3 years after primary immunization,respectively.About 3.0ml of venous blood was collected from each enrolled subject at pre-booster immunization,30 days after booster immunization and the serum was separated for neutralizing antibody detection.The antibody levels were used to evaluate the immunity persistence and immunogenicity after booster immunization of live attenuated varicella vaccines .
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
1,193
The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Xiangfu County Center for Disease Control and Prevention
Kaifeng, Henan, China
Immunogenicity index-seroconversion rate of antibody
seroconversion rates of antibody 1 year after primary immunization
Time frame: 1 year after primary immunization
Immunogenicity index-seroconversion rate of antibody
seroconversion rates of antibody 2 years after primary immunization
Time frame: 2 years after primary immunization
Immunogenicity index-seroconversion rate of antibody
seroconversion rates of antibody 3 years after primary immunization
Time frame: 3 years after primary immunization
Immunogenicity index-Seroconversion rate of antibody
Seroconversion rate of the neutralizing antibody 30 days after booster immunization
Time frame: 30 days after booster immunization
Immunogenicity index-seropositivity rate of antibody
Seropositivity rate of antibody 30 days after booster immunization
Time frame: 30 days after booster immunization
Immunogenicity index-Seropositivity rate of antibody
Seropositivity rate of antibody before booster immunization
Time frame: Before the booster dose immunization
Immunogenicity index-GMT of the antibody
GMT of the antibody before booster immunization
Time frame: Before the booster dose immunization
Immunogenicity index- GMT of the antibody
GMT of the antibody 30 days after booster immunization
Time frame: 30 days after booster immunization
Immunogenicity index- GMI of the antibody
GMI of the antibody 30 days after booster immunization
Time frame: 30 days after booster immunization
Safety index-Incidence of solicited local or systemic AE
Incidence of solicited local or systemic AE within 14 days after vaccination
Time frame: within 14 days after vaccination
Safety index-Incidence of local or systemic AE
Incidence of local or systemic AE within 30 days after vaccination
Time frame: within 30 days after vaccination
Safety index-Incidence of SAE
Incidence of SAE within 30 days after vaccination
Time frame: within 30 days after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.